Business Wire

PMI

16.7.2020 16:15:11 CEST | Business Wire | Press release

Share
PMI Launches “Our World Is Not an Ashtray” Initiative and Aims to Halve Plastic Litter from Products by 2025

Philip Morris International Inc. (PMI) (NYSE:PM) today launched “Our World Is Not an Ashtray,” a new global initiative to raise awareness and drive a long-term change in behavior and attitudes around cigarette butt littering. The initiative supports PMI’s litter reduction target—described in its Integrated Report 2019 —to achieve a 50 percent reduction of the plastic litter from its products by 2025 (vs. 2021 baseline). The initiative, launched on WorldNoAshtray.com , aims to educate the public about the environmental impact of cigarette butt littering and inspire adult smokers to change littering habits.

“We seek to make cigarette butt littering socially unacceptable,” said Huub Savelkouls, Chief Sustainability Officer at PMI. “‘Our World Is Not an Ashtray’ is an important initiative in our multipronged approach to addressing this important issue.”

To track progress against its goal, PMI is working with three organizations—Litterati , Cortexia , and CARTO —to implement a data-driven approach and assess the prevalence of cigarette butt litter across the globe; identify litter hotspots; and, monitor the impact of anti-littering activities. A pilot assessment will take place this summer in a pilot city before being rolled out in representative countries across the world in 2021 as part of a five year assessment.

Waste littering is a major environmental concern and was identified as an issue of growing importance for PMI following external assessments, and raised to priority status in its Sustainability Materiality Report at the end of 2019. In a new international study conducted by global research data and insights company Kantar this spring on behalf of PMI, 25 percent of adult smokers reported that they throw cigarette butts on the ground because they “think it is a normal way to dispose of a cigarette.”

The survey also revealed that 75 percent of respondents thought that cigarette filters are made of cotton or paper, and only 13 percent knew that filters are made of plastic. These findings highlight the need for awareness campaigns such as “Our World Is Not an Ashtray” to help change smokers’ behaviors.

Jeff Kirschner, Founder and CEO of Litterati, said: “There’s a widespread view that there’s nothing wrong with stubbing out cigarettes on streets or beaches, yet very few people realize that plastic is the main component in cigarette butts. Litterati began with just one person picking up a cigarette butt, and it has transformed into a global movement that’s empowering people to crowdsource-clean the planet. Together with PMI, we will use our technology to gather behavioral insight on cigarette butt littering, map problem areas, and mitigate future risk. We’re proud to be part of ‘Our World Is Not an Ashtray’ to help address cigarette butt litter worldwide.”

PMI is increasing the scale and reach of its participation in clean-up activities, to raise awareness of the issues of littering—and cigarette butt littering particularly—in local communities. Working with Litterati, PMI will encourage volunteers in every corner of the world to use the organization’s app to geotag litter and join cleanup challenges ranging from local neighborhoods to global initiatives. PMI’s affiliates will also work with local anti-littering organizations, following the participation of over 3,900 PMI volunteers from 31 countries in litter collections on World Cleanup Day 2019 where they collected 83 tons of litter.

Jens Rupp, PMI’s Head of Environmental Sustainability, said: “Cigarette butt litter is a problem that we need to solve; too many cigarette butts are littered, ending up in the natural environment. By working with experts to better understand how to nudge smokers to more responsible disposal habits, launching general population education programs, and cooperating with governments and local authorities to ensure there is an adequate waste disposal infrastructure, we can reduce the plastic litter associated with our products.”

For more on the “Our World Is Not an Ashtray” initiative, visit www.worldnoashtray.com .

For additional information about PMI’s efforts to reduce waste littering and the CBL study, visit www.pmi.com/littering .

Survey Methodology
The global survey was conducted by Kantar, between the third week of March and the first week of May 2020; 12,800 people across 10 countries were questioned, with a 54 percent completion rate. The completion rate reflects the respondents who finished the survey, matched the eligible criteria, provided quality data, and filled quotas considered nationally representative by Kantar (gender and age).

Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. For more information, please visit www.pmi.com and www.pmiscience.com.

###

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye